A Phase 3, Randomized, Open-Label, Multicenter, Active-controlled Trial Comparing Efficacy and Safety of THDB0206 Injection With Insulin Lispro Injection Combined With Insulin Glargine Injection U-100 in Chinese Participants With Type 2 Diabetes
Latest Information Update: 25 Dec 2025
At a glance
- Drugs Insulin lispro (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Tonghua Dongbao Pharmaceutical
Most Recent Events
- 22 Dec 2025 Status changed from active, no longer recruiting to completed.
- 15 Oct 2025 Top line results from Type 1 diabetes mellitus and Type 2 diabetes mellitus presented in the Adocia media release.
- 25 Sep 2025 According to an Adocia media release, The final dosing of the last Type 2 Diabetes patient was announced on December 12, 2024.